Capricor Therapeutics Inc (CAPR) fair value: what the stock is really worth
As of Nov 20, 2026: fair value (intrinsic value) of Capricor Therapeutics Inc stock $5.35, price $7.59, that is 29.5% below the price, quality 23 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Capricor Therapeutics Inc
CAPR · USExpensive (fair value 30% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 21, 2026.
How to read this chart
60‑month range $2.71 – $35.34 · fair‑value band $4.01 – $6.69 · the $7.59 price screens above the $5.35 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 21, 2026.
Every Wednesday you see whether Capricor Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Show moreShow less
Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial.
In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform.
The company was founded in 2005 and is headquartered in San Diego, California.
Stock analysis
Capricor Therapeutics Inc (CAPR) currently trades at $7.59, while our estimate is $5.35, 30% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $4.01 (bear) to $6.69 (bull), the price of $7.59 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2017: revenue and profit before it include the divested business. Growth is measured afresh from 2017.
Capricor Therapeutics Inc reported revenue of $0 in FY2025 versus $245K in FY2021. Reported net income was −$105M in FY2025.
Key figures
Market cap $595M Small · P/S ratio 53.5 · EPS (TTM) $-2.65 · Return on equity −100% · Return on assets (EBIT) −41.3% (5-year average) · Revenue (TTM) $11.1M · Revenue growth (quarter YoY) −7.9% · Free cash flow −$72.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 79% below its 52-week high and 97% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −30%, CAPR screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 2 officers or directors sold shares worth $1.5M and none bought.
- SaleKaren KrasneyEVP, GENERAL COUNSEL4× since Mar 31, 2026: 75,000 shares, avg. $30.73$2.3MJun 25, 202610b5-1 plan
- SaleAnthony BergmannCHIEF FINANCIAL OFFICER4× since Mar 31, 2026: 75,000 shares, avg. $30.73$2.3MJun 25, 202610b5-1 plan
- SaleKarimah Es SabarDirector2× since Mar 31, 2026: 122,529 shares, avg. $30.66$3.8MApr 2, 202610b5-1 plan
Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 20, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Capricor Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 854 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $920.69 | $1,275.02 | +38% | vs CAPR |
| Vertex Pharmaceuticals Incorporated VRTX | $515.02 | $566.52 | +10% | vs CAPR |
| Samsung Biologics Co 207940 | ₩1,355,000 | ₩1,490,500 | +10% | vs CAPR |
| argenx SE ARGX | $925.70 | $908.40 | −2% | vs CAPR |
| CSL Limited CSL | A$197.29 | A$188.80 | −4% | vs CAPR |
| BeOne Medicines AG 6160 | HK$230.80 | HK$152.92 | −34% | vs CAPR |
| Moderna, Inc MRNA | $195.00 | $119.97 | −38% | vs CAPR |
| Revolution Medicines, Inc RVMD | $161.20 | $83.14 | −48% | vs CAPR |
| Celltrion, Inc 068270 | ₩213,000 | ₩74,574 | −65% | vs CAPR |
| Royalty Pharma plc RPRX | $68.45 | $19.01 | −72% | vs CAPR |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Capricor Therapeutics Inc (CAPR) overvalued or undervalued?
What is the fair value of CAPR?
What is the quality score of CAPR?
What is the price target for Capricor Therapeutics Inc (CAPR)?
What is the Capricor Therapeutics Inc stock forecast for 2026?
What is the revenue of Capricor Therapeutics Inc (CAPR)?
What is the intrinsic value of Capricor Therapeutics Inc (CAPR)?
Is Capricor Therapeutics Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of CAPR?
How much is Capricor Therapeutics Inc worth?
What do the bullish and bearish scenarios say about CAPR?
What is the PEG ratio of CAPR?
How solid is the balance sheet of Capricor Therapeutics Inc (CAPR)?
How far is CAPR from its 52-week high?
Which stocks are comparable to Capricor Therapeutics Inc?
Is Capricor Therapeutics Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Capricor Therapeutics Inc (CAPR)?
What should I pay attention to with Capricor Therapeutics Inc right now?
Key figures of Capricor Therapeutics Inc
How large is the market capitalisation of Capricor Therapeutics Inc (CAPR)?
What is the P/S ratio of Capricor Therapeutics Inc (CAPR)?
What are the earnings per share of Capricor Therapeutics Inc (CAPR)?
What is the return on equity of Capricor Therapeutics Inc (CAPR)?
What is the EBIT return on assets of Capricor Therapeutics Inc (CAPR)?
How fast is revenue growing at Capricor Therapeutics Inc (CAPR)?
How much free cash flow does Capricor Therapeutics Inc (CAPR) generate?
How much net cash does Capricor Therapeutics Inc (CAPR) hold?
Watch Capricor Therapeutics Inc in the live analysis
One click puts Capricor Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.